SEATTLE, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Data Bridge Market Research Published Latest Global Pharmacogenetics Testing in Psychiatry/Depression Market Study by in-depth analysis of the current ...

Global Pharmacogenetics Testing in Psychiatry/Depression Market is expected to reach the value of USD 2,133.49 million by 2029, at a CAGR of 9.5% during the forecast period. Anxiety accounts for the ...

Personalized medicine is the unique tailoring of medical treatment to a patient’s individual symptoms AND their genetic profiles. What was once thought of as science fiction is no longer a fantasy - ...

A new U.S. Department of Veterans Affairs study found that pharmacogenomic testing can help providers avoid prescribing antidepressant medications that may have undesirable outcomes. Pharmacogenomics ...

The test would be able to tell doctors how the patient metabolizes a certain medication(Photo by Polina Tankilevitch, Pexels) Pharmacogenomic testing can help ...

Gangdong-gu, Seoul (Mayor Lee Soo-hee) announced on the 8th that it will support mental health services that provide depression screening, in-depth psychological counseling, and treatment cost support ...

A new VA study found that pharmacogenomic testing can help providers avoid prescribing antidepressant medications that may have undesirable outcomes. Pharmacogenomics is the study of how genes affect ...

A special kind of genetic test that helps determine the best antidepressant for patients with moderate-to-severe depression could generate substantive health system savings and greatly improve patient ...

New research from the University of B.C. shows that a type of genetic testing could benefit patients with depression, and aid physicians in prescribing the most effective medications. The bottom line ...

Acquisitions, partnerships, and collaborations were among the market’s inorganic growth strategies. As a result of these activities, Europe Pharmacogenetics Testing in Psychiatry/Depression market ...